Serum biomarkers to monitor Becker muscular dystrophy


  • In patients with Becker muscular dystrophy (BMD), creatine/creatinineratio(Cr/Crn) and myostatin can reasonably predict patients’ functional performance after adjusting for age.

Why this matters?

  • Clinical trials in BMD have been met with challenges such as very low recruitment, difficulty with demonstrating treatment efficacy for example. Objective biomarkers are still lacking.  

  • Cr/Crn and myostatin can potentially serve as monitoring biomarkers in patients with BMD.